Stock Events

Stock Events

Vertex Pharmaceuticals 

€481.95
1258
-€5.75-1.18%Friday 07:16

Statistics

Day High
481.95
Day Low
481.95
52W High
498.55
52W Low
352.85
Volume
-
Avg. Volume
-
Mkt Cap
122.16B
P/E Ratio
33.26
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 9Expected
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
3.63
3.85
4.08
4.31
Expected EPS
3.7946891038
Actual EPS
N/A

Financials

32.75%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
10.42BRevenue
3.41BNet Income

Analyst Ratings

$434.10Average Price Target
The highest estimate is ⁦504.60⁩.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
17%
Sell
8%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VX1.MU. It's not an investment recommendation.
Microsoft
347
MSFT
NVIDIA
340
NVDA
Amazon
311
AMZN
Apple
286
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences competes in the antiviral drug market, similar to Vertex's focus on cystic fibrosis and other diseases.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the biopharmaceutical field, focusing on treatments for conditions like cystic fibrosis, where Vertex has significant investments.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, competing in areas of genetic disorders and diseases, overlapping with Vertex's market.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes in the biotech sector, focusing on innovative therapies that could rival Vertex's treatments for genetic diseases.
Biogen
BIIB
Mkt Cap37.49B
Biogen competes in the biotechnology and pharmaceuticals sector, focusing on neurological diseases, a potential competition area for Vertex.
Merck
MRK
Mkt Cap368.89B
Merck & Co. competes across a broad range of therapeutic areas, including those where Vertex is seeking to expand its portfolio.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes in various therapeutic areas, including genetic disorders, posing competition to Vertex's niche markets.
Novartis
NVS
Mkt Cap303.67B
Novartis competes in multiple segments including treatments for genetic diseases, directly competing with Vertex's portfolio.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in various therapeutic areas, including respiratory diseases, which could overlap with Vertex's cystic fibrosis treatments.

About

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
Show More
CEO
Reshma Kewalramani
Employees
6400
Country
United States
ISIN
US92532F1003
WKN
000882807

Listings

BA
AR
VRTX.BA
XNAS
US
VRTX
STU
DE
VX1.STU
LSE
GB
0QZU.LSE

0 Comments

Share your thoughts

FAQs

What is Vertex Pharmaceuticals stock price today?▼
The current price of VX1.MU is €481.95 EUR — it has decreased by -1.18% in the past 24 hours. Watch Vertex Pharmaceuticals stock price performance more closely on the chart.
What is Vertex Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Vertex Pharmaceuticals stocks are traded under the ticker VX1.MU.
What is Vertex Pharmaceuticals market cap?▼
Today Vertex Pharmaceuticals has the market capitalization of 122.16B
When is the next Vertex Pharmaceuticals earnings date?▼
Vertex Pharmaceuticals is going to release the next earnings report on February 9, 2027.
What were Vertex Pharmaceuticals earnings last quarter?▼
VX1.MU earnings for the last quarter are 4.25 EUR per share, whereas the estimation was 4.3 EUR resulting in a -1.19% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Vertex Pharmaceuticals revenue for the last year?▼
Vertex Pharmaceuticals revenue for the last year amounts to 10.42B EUR.
What is Vertex Pharmaceuticals net income for the last year?▼
VX1.MU net income for the last year is 3.41B EUR.
How many employees does Vertex Pharmaceuticals have?▼
As of November 8, 2026, the company has 6,400 employees.
In which sector is Vertex Pharmaceuticals located?▼
Vertex Pharmaceuticals operates in the Health & Wellness sector.
When did Vertex Pharmaceuticals complete a stock split?▼
Vertex Pharmaceuticals has not had any recent stock splits.
Where is Vertex Pharmaceuticals headquartered?▼
Vertex Pharmaceuticals is headquartered in BOSTON, United States.